{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Cancer+or+Locally+Advanced&page=2", "query": { "condition": "Metastatic Cancer or Locally Advanced", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Cancer+or+Locally+Advanced&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-22T12:06:38.702Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02589717", "title": "An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "Atezolizumab [TECENTRIQ]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2015-11", "completion_date": "2016-08", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-07-22T12:06:38.702Z", "location_count": 40, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 35 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02589717" }, { "nct_id": "NCT06997497", "title": "A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colon Adenocarcinoma", "Rectal Adenocarcinoma" ], "interventions": [ { "name": "Calderasib", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin/levofolinate calcium", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Bevacizumab biosimilar", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 477, "start_date": "2025-07-16", "completion_date": "2030-10-27", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-07-22T12:06:38.702Z", "location_count": 31, "location_summary": "Los Angeles, California • Fort Collins, Colorado • Lone Tree, Colorado + 27 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06997497" }, { "nct_id": "NCT06428396", "title": "Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Belzutifan", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2024-11-27", "completion_date": "2028-12-25", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-07-22T12:06:38.702Z", "location_count": 14, "location_summary": "Goodyear, Arizona • Beverly Hills, California • La Jolla, California + 11 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06428396" }, { "nct_id": "NCT00242203", "title": "Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Zometa", "type": "DRUG" }, { "name": "Epirubicin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "External beam radiation", "type": "RADIATION" }, { "name": "Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 120, "start_date": "2002-10", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2013-08-13", "last_synced_at": "2026-07-22T12:06:38.702Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00242203" }, { "nct_id": "NCT03448042", "title": "A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Runimotamab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 123, "start_date": "2018-06-06", "completion_date": "2027-11-30", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-07-22T12:06:38.702Z", "location_count": 5, "location_summary": "New Haven, Connecticut • Saint Louis, Michigan • New York, New York + 2 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Saint Louis", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03448042" }, { "nct_id": "NCT01609127", "title": "Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Non-resectable Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Tesetaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genta Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 213, "start_date": "2012-05", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2012-06-01", "last_synced_at": "2026-07-22T12:06:38.702Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01609127" }, { "nct_id": "NCT00055861", "title": "Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 27, "start_date": "2002-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-07-22T12:06:38.702Z", "location_count": 2, "location_summary": "Aurora, Colorado • Columbus, Ohio", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00055861" }, { "nct_id": "NCT04504942", "title": "Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "Leronlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CytoDyn, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2020-05-01", "completion_date": "2025-01-27", "has_results": true, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-07-22T12:06:38.702Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04504942" }, { "nct_id": "NCT06224673", "title": "ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2 Low Breast Carcinoma", "Triple Negative Breast Cancer", "Hormone-receptor-positive Breast Cancer", "Hormone Receptor Positive Breast Carcinoma" ], "interventions": [ { "name": "ARX788", "type": "DRUG" }, { "name": "Computed Tomography (CT)", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Amiloride", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Laura Huppert, MD, BA", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2026-06-05", "completion_date": "2029-11-30", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-07-22T12:06:38.702Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06224673" }, { "nct_id": "NCT05634954", "title": "Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "GEH121224 (18F) Injection", "type": "DRUG" }, { "name": "Dynamic and Static - PET/CT Scan", "type": "DIAGNOSTIC_TEST" }, { "name": "Static - PET/CT Scan", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "GE Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2026-02", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-10-23", "last_synced_at": "2026-07-22T12:06:38.702Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05634954" } ] }